SODIUM BICARBONATE

1. PURPOSE

To authorize CCP’s to monitor and adjust existing Sodium Bicarbonate infusions

2. POLICY

2.1. CCP’s are permitted to monitor or discontinue Sodium Bicarbonate infusions during transport
2.2. CCP’s may not initiate Sodium Bicarbonate infusions
2.3. CCP’s may administer intravenous push dose Sodium Bicarbonate for crush injuries

3. PRECAUTIONS

3.1. Extravasation into subcutaneous tissues may cause small vein sclerosis and local chemical

burns.

3.2. Use only 4.2% Sodium Bicarbonate in newborns due to intracranial hemorrhage concerns
3.3. In cases of overcompensation resulting in metabolic alkalosis presenting as impaired tissue

perfusion, hypokalemia, hypocalcemia, decrease in patient’s fibrillation threshold, sodium and
water overload, the infusion will be discontinued, and the transferring physician or base
hospital notified.

4. PROCEDURE

4.1. The infusion concentration and regulation of the infusion rate will occur within the parameters

as defined by the transferring physician or base hospital.

4.2. For crush injuries and transport times >30 minutes, CCP may consider a bolus dose of 50-

100 meq.

27

